Dr. Filips is the principal founder, Vice-Chairman, President, and CMO of iTraumaCare. Dr. Filips, a trauma surgeon, retired from the Canadian Forces (CF) after 20 years of service, completing tours
in Afghanistan, Bosnia, and the Golan Heights. He created the Tactical Combat Casualty Care training program, created and chaired the Combat Casualty Working Group for the Canadian Forces, and was a member of the Combat Casualty Care research steering committee for Canada, US, UK, Australia, and New Zealand. Dr. Filips recently carried out consulting research work for Defence Research and Development Canada (DRDC) on combat injury assessment and prevention research. Prior to this, he published research findings on hypertonic ﬂuid resuscitation and hemorrhage control with tourniquets. Dr. Filips is currently serving as a course director for Advanced Trauma Life Support (ATLS) courses at the University of Alberta and Tactical Medicine courses for the military and tactical police. He also worked in Haiti with the Red Cross as the chief surgeon at the Notre Dame Hospital in Petit Goave post-earthquake and is a member of the management team for the Canadian Red Cross rapid deployment field hospital. He has practiced trauma and general surgery at St. Michael’s hospital in Toronto, St. Joseph’s Health Centre in Toronto, and at the University of Alberta in Edmonton. In addition to a trauma fellowship at Sunnybrook & Women’s College Health Sciences Centre in Toronto, ON in 2002, he has completed several military trauma-training courses in Los Angeles, CA, Geneva, Switzerland, and London, UK. He completed his general surgery residency at the University of Toronto in 2001 and medical school at Queen’s University (Kingston, ON) in 1991.
Dr. Atkinson brings extensive industry experience in technology development, project management, and systems optimization across a broad range of medical, drug development, genomics
and biological applications. Prior to founding iTraumaCare, Dr. Atkinson was the chief scientific officer of Biobasix Solutions Inc., a management consulting firm that developed novel therapeutics for rare diseases. His experience includes roles of increasing responsibility in companies including Spiritus Diagnostics, Illumina, Molecular Dynamics/Amersham Pharmacia, and Ignition Sequence. He holds a combined PhD in Genetics and Biological Sciences from the University of Alberta and conducted his post-doctoral research at the University of California, Berkeley.
Chief Executive Officer
Chief Operating Officer
CFO & Chairman of the Board
Chief Executive Officer
President & Chief Executive Officer Dave Schneider has extensive experience developing and delivering solutions to “hard problems” around the globe. His career includes service as a US Army Special Forces 18-Delta “Green Beret,” international advise and assist work, remote medicine educator, and founder of several for-profit and non-profit organizations. Dave was the first to use the iTClamp in the field and has worked with the company for many years prior to becoming CEO and lead investor post-restructure.
Previously, he co-founded Eight32 Group and Jedburgh Life Systems to develop and deliver unconventional solutions to difficult problems. Dave is a recognized and sought-after TCCC and Prolonged Field Care subject matter expert in both consulting and operational capacities. He consults on advanced field medical projects for the Department of Defense, including pre-hospital automated critical care, AI application, and hemorrhage control best practices. Dave holds a BA in Modern Foreign Languages (Russian) and a BBA in Finance from James Madison University. He is a US Special Operations Command Advanced Tactical Practitioner, EMT-Paramedic, Certified Remote Medical Practitioner with the International Society of Remote Medical Practitioners, and Prolonged Field Care Subject Matter Expert. He was awarded the Bronze Star with “V” device for combat valor. Dave is also a proud Eagle Scout, Order of the Arrow Brotherhood, Boy Scouts of America.
Chief Operating Officer
With over a decade of experience as a high-impact Chief Operating Officer, Maggie Pemberton has consistently demonstrated her ability to drive impressive annual sales exceeding $50 million and to lead and manage teams of more than 600 professionals. Her expertise in optimizing operations and streamlining processes has yielded substantial results. She has played a pivotal role in steering organizations toward success, fostering profitability, building a culture of winning, and achieving operational excellence.
Maggie has had the privilege of spearheading key initiatives that have led to significant achievements, such as double-digit year-over-year sales increases, improved profitability, and increased employee retention. These accomplishments showcase her dedication to strategic growth and operational excellence, aligning perfectly with her goal to take ITC to the next level of success. In dynamic, fast-paced environments, she excels in guiding teams and operations to achieve exceptional results.
Maggie holds a Juris Doctor (JD) degree from the Cumberland School of Law and earned both her Master of Science (MS) and Bachelor of Science (BS) degrees in Education from the University of Florida. Her diverse educational background equips her with a unique skill set, enabling her to approach leadership challenges with a well-rounded perspective.
Beyond her professional accomplishments, Maggie is actively involved in her local church community and takes pride in her membership in the Junior League of Birmingham. She is deeply rooted in Trussville, Alabama, where she resides with her husband, Tim, and their five children.
Chief Financial Officer & Chairman of the Board
Paul has more than two decades of CEO-level experience co-founding, financing, managing, and exiting medical device and diagnostic companies, as well as founding the Targeted Technology Funds, San Antonio’s first life-science dedicated venture capital firm, where Paul served as the Senior Managing Partner. Targeted is an investor in ITC, as well as other device companies such as Vidacare, ENTrigue Surgical, Aerin, and Xenex.
Companies Paul has co-founded include Xenotope Diagnostics, which developed the first FDA-approved rapid test for Trichomonas (licensed to Genzyme Diagnostics, now Sekisui), CardioSpectra, a cardiac OCT imaging company (sold to Volcano Corporation, now Philips), BiO2 Medical, which developed the first FDA-approved device for the prevention of pulmonary embolism (sold to Mermaid Medical), and Viroxis Corporation (with its spin-off, Santalis Pharmaceuticals), a dermatological drug development company (sold to TFS Corporation of Australia).
Paul received his PhD in Cell Biology and Genetics from the Cornell University Medical College in Manhattan, where he was the first-ever recipient of the Weill Graduate School Award of Excellence. He received his MBA from the University of Texas at San Antonio and his BSc in Biochemistry (Hons) from the University of London. Paul holds over a dozen issued US patents and in 2008 was inducted into San Antonio’s “SATAI Technology Hall of Fame.”
Joe Brennan is the Avalon Action Alliance’s first CEO, one carefully chosen to guide its next phase: from proof-of-concept launch to scaling as a sustainable national leader. Joe has a driving passion for solving the nation’s mental health and mild traumatic brain injury system failing many of our country’s military and first responders. He has seen how these can cascade into generational impacts on families and communities. He brings over three decades of relevant healthcare business, Naval service, and personal concussion experience to Avalon. As a CEO, founder, and growth driver in the medical and pharmaceutical arena, he launched and scaled healthcare companies, gathered clinical and programmatic data to influence standards of care, and forged strong funding models across philanthropic, government, and private sectors.
Joe became the CEO of Avalon in October 2022. Previously, he served as CEO of Innovative Trauma Care and neoSurgical, and he held senior management positions with Sanofi (formerly Genzyme) and 3M KCI (formerly Acelity), among others. At Innovative Trauma Care, he drove the process to gain US government approval for an innovative hemorrhage control device. At Sanofi, he grew the biosurgical division’s commercial sales from $10 million to over $100 million and supervised multiple diverse teams throughout his 17-year tenure. At 3M KCI, he achieved year-to-year commercial growth for skin substitute and wound care product lines. Joe is a graduate of the United States Naval Academy. He served in Operation Desert Storm as a Division Officer on the USS Frederick and worked with the Chief of Naval Operations in the Foreign Liaison Office. He has an MBA from the Goizueta Business School at Emory University. He is a former college football player and a family man. He resides in Atlanta and is married with six kids and an animal menagerie, which currently includes two dogs, two cats, fish, frogs, and a tortoise.
Jim Traa is a recognized life science industry veteran with over 35 years in top-level executive and leadership positions with publicly traded and privately held companies. Jim is a Managing Partner of San Antonio’s first life science dedicated venture capital firm, the Targeted Technology Funds, and served in senior executive management positions in several of the funds’ portfolio companies. Jim was also the Chief Operating Officer for Luminus Biosciences, Inc., a pre-clinical nanotechnology oncology drug development company, as well as the Co-Founder and Chief Operating Officer of Rhapsody Labs. Prior to Luminus, Jim was a Vice President for the molecular profiling company, Caris Life Sciences. Prior to Caris, Jim held numerous senior leadership positions within Sanofi Genzyme’s Biosurgical Specialties business unit.
Jim is a Gulf War Veteran who served his country as a Commissioned Officer in the United States Navy. Jim earned his Bachelor of Science from the United States Naval Academy, Annapolis, and Master of Business Administration from the University of Texas, San Antonio. Jim continues to serve on numerous non-profit and private company boards and resides in San Antonio with his wife and three children.
Mr. Pinsent is a Chartered Professional Accountant. In 2004, he became a founding partner with St. Arnaud Pinsent Steman Chartered Professional Accountants, following a 10-year career with Ernst and Young LLP. Mr. Pinsent earned a BEd and BComm (AD) from the University of Alberta, has an ICD.D designation from the Institute of Corporate Directors, and became an FCPA in 2013.
Mr. Pinsent sits on the board of directors of several public and private companies and supports numerous non-profit and philanthropic initiatives. He has experience as a board and audit committee chair and has extensive experience in compliance and corporate governance in the public markets. John is a father of five and a grandfather of three and freely admits that his love for golf far outweighs his abilities in the sport.